JNJ vs NXL · P/E 17, rev $49.37B vs rev $301.6K
Johnson & Johnson (JNJ) versus Nexalin Technology Inc. (NXL) — a side-by-side from cached financials, not a winner call.
Johnson & Johnson (JNJ) is a drug manufacturers - general company listed on US. It is led by Joaquin Duato.
Nexalin Technology Inc. (NXL) is a medical devices company listed on NASDAQ.
Latest reported JNJ revenue for 2026-06-28 was $49.37B. Net income was $10.77B. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
Latest reported NXL revenue for 2025-12-31 was $301.6K. Net income was -$8.2M. Revenue was up 78.8% from 2024-12-31 to 2025-12-31. NXL currently screens at market cap $8.5M.
JNJ currently screens at market cap $375.37B and trailing P/E 17.4. NXL currently screens at market cap $8.5M.
Not investment advice. Open the JNJ and NXL stock pages for the full models.
Not investment advice.